Y Intercept Hong Kong Ltd Acquires 16,115 Shares of Illumina, Inc. (NASDAQ:ILMN)

Y Intercept Hong Kong Ltd increased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 506.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 19,300 shares of the life sciences company’s stock after acquiring an additional 16,115 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Illumina were worth $2,579,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. Empowered Funds LLC increased its position in Illumina by 1.7% during the third quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock worth $516,000 after acquiring an additional 66 shares during the period. Bank of Stockton raised its position in shares of Illumina by 3.8% in the 4th quarter. Bank of Stockton now owns 2,162 shares of the life sciences company’s stock valued at $289,000 after buying an additional 80 shares in the last quarter. Caprock Group LLC lifted its holdings in shares of Illumina by 3.0% during the 3rd quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock worth $376,000 after acquiring an additional 83 shares during the period. Integrated Advisors Network LLC lifted its holdings in shares of Illumina by 2.0% during the 3rd quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock worth $585,000 after acquiring an additional 90 shares during the period. Finally, Stephens Inc. AR lifted its holdings in shares of Illumina by 1.4% during the 4th quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company’s stock worth $885,000 after acquiring an additional 90 shares during the period. 89.42% of the stock is owned by institutional investors.

Illumina Stock Down 0.3 %

Shares of NASDAQ:ILMN opened at $93.96 on Tuesday. The firm has a market cap of $14.88 billion, a P/E ratio of -12.23, a P/E/G ratio of 1.60 and a beta of 1.10. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 12-month low of $92.20 and a 12-month high of $156.66. The business has a fifty day simple moving average of $126.97 and a 200 day simple moving average of $133.99.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on ILMN. UBS Group upped their target price on Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Barclays downgraded Illumina from an “equal weight” rating to an “underweight” rating and reduced their target price for the company from $130.00 to $100.00 in a report on Monday, February 10th. Royal Bank of Canada reduced their target price on Illumina from $250.00 to $247.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Morgan Stanley reduced their target price on Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 11th. Finally, JPMorgan Chase & Co. raised their target price on Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Illumina currently has an average rating of “Moderate Buy” and a consensus price target of $159.45.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.